Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - AleAnna, Inc. (0001845123) (Issuer)
4 - AleAnna, Inc. (0001845123) (Issuer)
4 - AleAnna, Inc. (0001845123) (Issuer)
CERT - AleAnna, Inc. (0001845123) (Filer)
15-12G - AleAnna, Inc. (0001845123) (Filer)
8-A12B - AleAnna, Inc. (0001845123) (Filer)
Combination brings emerging leader in Italian natural gas and renewable natural gas to public marketsShares of AleAnna, Inc. to begin trading on Nasdaq on December 16 under the ticker symbol "ANNA"AleAnna stands on the cusp of a major milestone, with the first phase of natural gas production from the Longanesi Field projected to commence in Q1 2025 DALLAS and VANCOUVER, British Columbia and ROME, Dec. 13, 2024 (GLOBE NEWSWIRE) -- AleAnna, Inc. (together with its subsidiaries, "AleAnna" or the "Company"), an emerging leader in Italy's energy landscape, announced the completion of the previously announced business combination (the "Business Combination") between Swiftmerge Acquisition Corp.
$480 million Business Combination to Accelerate the Commercialization of an Innovative FDA-Approved Cardiovascular Disease Treatment HDL Therapeutics, Inc. ("HDL Therapeutics"), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia (HoFH), has signed a definitive merger agreement with Swiftmerge Acquisition Corp. (NASDAQ:IVCP) ("Swiftmerge"), a special purpose acquisition company with a disruptive consumer healthcare focused team. Under the terms of the merger agreement, a wholly-owned subsidiary of Swiftmerge will
NASDAQ IVCP Swiftmerge Acquisition Corp ("Swiftmerge"), a $225 million innovative healthcare investment corporation and a special purpose acquisition company, announced today the signing of a non-binding letter of intent ("LOI") for a business combination with HDL Therapeutics Inc. ("HDL Therapeutics"), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy for reducing coronary atheroma in homozygous familial hypercholesterolemia (HoFH) patients. HDL Therapeutics' platform, removes the highest risk plaques in coronary arteries that tend to rupture causing heart attacks and stroke. HDL expects this platform to have significant implications in the futur
SC 13G/A - Swiftmerge Acquisition Corp. (0001845123) (Subject)
SC 13G/A - Swiftmerge Acquisition Corp. (0001845123) (Subject)
SC 13G/A - Swiftmerge Acquisition Corp. (0001845123) (Subject)